Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vion (formerly Oncorx) interesting play on Gene Therapy -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (104)	5/14/1998 10:31:00 AM
From: Arthur Radley	Respond to of 370

Finally got my investor packet yesterday. Appears they have great potential with an NDA coming next year. Has anyone heard about the cosmetic company introducing any products in the near future.

To: Jim Oravetz who wrote (104)	8/13/1998 12:32:00 PM
From: Jim Oravetz	Read Replies (2) \| Respond to of 370

Here is the latest news on Class B Stock: Vion Class B Conv Pfd Stk Hldrs To Convert Shrs To Cmn Stk Dow Jones Newswires NEW HAVEN, Conn. -- Vion Pharmaceuticals Inc.'s (VION) holders of Class B Convertible Preferred Stock agreed to convert their shares into Vion common shares, effective immediately. In a press release Thursday, Vion said investors will receive a total of 1.7 million common shares. Vion said the transaction was designed to minimize the potential dilutive effect which could have resulted from the prior structure of the Class B convertible preferred stock. After the conversion, the company will no longer have preferred stock with variable conversion rates. It will have 13.9 million common shares outstanding. Nasdaq-listed Vion shares recently traded at 3 1/4, down 3/16, on volume of 5,500 shares